More About Epidemiology & Biostatistics Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

Andy Ni

Assistant Attending Biostatistician

Andy Ni, Assistant Attending Biostatistician

Office Phone



University of North Carolina at Chapel Hill

Current Research Interests

Dr. Ni’s methodological research interests are in the design and analysis of large-scale observational studies with survival outcomes. He is particularly interested in statistical methodologies related to case-cohort and nested case-control designs. Dr. Ni’s interests also lie in regularized variable selection in survival analysis with high-dimensional data. He collaborates with clinical researchers in the Thoracic Oncology Service and the Lymphoma Service at Memorial Sloan Kettering in the design and analysis of clinical trials of different phases and observational studies.


Selected peer-reviewed publications:


  1. A. Ni and J. Cai. “Tuning parameter selection in Cox proportional hazards model with a diverging number of parameters.” Scandinavian Journal of Statistics, accepted.

  2. A. Ni and J. Cai. “A regularized variable selection procedure in additive hazards model with stratified case-cohort design.” Lifetime Data Analysis. 2017 Jul 28. [Epub ahead of print].

  3. A. Ni, J. Cai, D. Zeng. “Variable selection for case-cohort studies with failure time outcome”. Biometrika. 2016; 103 (3): 547-562. [R package]


  1. E.J. Jordan, H.R. Kim, M.E. Arcila, D. Barron, D. Chakravarty, J. Gao, M.T. Chang, A. Ni, …, G. Riely. “Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies.” Cancer Discovery. 2017; 7(6): 596—609.

  2. A. Drilon, N. Rekhtman, M. Arcila, L. Wang, A. Ni, M. Albano, M.V. Voothuysen, R. Somwar, R. Smith, J. Montecalvo, A. Plodkowski, M. Ginsberg, G. Riely, C.M. Rudin, M. Ladanyi, M. Kris. “A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers”. Lancet Oncology. 2016; 17(12): 1653—1660.

For a complete list of publications: